OBJECTIVES: Ubiquitin carboxyl-terminal esterase-L1 (UCHL1) is a protein highly selectively expressed in neurons and has been linked to neurodegenerative disease in humans. We hypothesize that UCHL1 would be an effective serum biomarker for brain injury as tested in canine models of hypothermic circulatory arrest (HCA) and cardiopulmonary bypass (CPB). METHODS: Dogs were exposed to CPB (n = 14), 1 hour of HCA (1h-HCA; n = 11), or 2 hours of HCA (2h-HCA; n = 20). Cerebrospinal fluid and serum were collected at baseline, 8 hours, and 24 hours after treatment. UCHL1 levels were measured using a sandwich enzyme-linked immunosorbent assay. Neurologic function and histopathology were scored at 24 hours, and UCHL1 immunoreactivity was examined at 8 hours. RESULTS: Baseline UCHL1 protein levels in cerebrospinal fluid and serum were similar for all groups. In serum, UCHL1 levels were elevated at 8 hours after treatment for 2h-HCA subjects compared with baseline values (P < .01) and also compared with CPB dogs at 8 hours (P < .01). A serum UCHL1 level above 3.9 ng/(mg total protein) at 8 hours had the best discriminatory power for predicting functional disability. In cerebrospinal fluid, UCHL1 was elevated in all groups at 8 hours after treatment compared with baseline (P < .01). However, UCHL1 levels in cerebrospinal fluid remained elevated at 24 hours only in 2h-HCA subjects (P < .01). Functional and histopathologic scores were closely correlated (Pearson coefficient, 0.66; P < .01) and were significantly worse in 2h-HCA animals. CONCLUSIONS: This is the first report associating elevated serum UCHL1 with brain injury. The novel neuronal biomarker UCHL1 is increased in serum 8 hours after severe neurologic insult in 2h-HCA animals compared with CPB animals. These results support the potential for use in cardiac surgery patients and form the basis for clinical correlation in humans.
OBJECTIVES:Ubiquitin carboxyl-terminal esterase-L1 (UCHL1) is a protein highly selectively expressed in neurons and has been linked to neurodegenerative disease in humans. We hypothesize that UCHL1 would be an effective serum biomarker for brain injury as tested in canine models of hypothermic circulatory arrest (HCA) and cardiopulmonary bypass (CPB). METHODS:Dogs were exposed to CPB (n = 14), 1 hour of HCA (1h-HCA; n = 11), or 2 hours of HCA (2h-HCA; n = 20). Cerebrospinal fluid and serum were collected at baseline, 8 hours, and 24 hours after treatment. UCHL1 levels were measured using a sandwich enzyme-linked immunosorbent assay. Neurologic function and histopathology were scored at 24 hours, and UCHL1 immunoreactivity was examined at 8 hours. RESULTS: Baseline UCHL1 protein levels in cerebrospinal fluid and serum were similar for all groups. In serum, UCHL1 levels were elevated at 8 hours after treatment for 2h-HCA subjects compared with baseline values (P < .01) and also compared with CPB dogs at 8 hours (P < .01). A serum UCHL1 level above 3.9 ng/(mg total protein) at 8 hours had the best discriminatory power for predicting functional disability. In cerebrospinal fluid, UCHL1 was elevated in all groups at 8 hours after treatment compared with baseline (P < .01). However, UCHL1 levels in cerebrospinal fluid remained elevated at 24 hours only in 2h-HCA subjects (P < .01). Functional and histopathologic scores were closely correlated (Pearson coefficient, 0.66; P < .01) and were significantly worse in 2h-HCA animals. CONCLUSIONS: This is the first report associating elevated serum UCHL1 with brain injury. The novel neuronal biomarker UCHL1 is increased in serum 8 hours after severe neurologic insult in 2h-HCA animals compared with CPB animals. These results support the potential for use in cardiac surgery patients and form the basis for clinical correlation in humans.
Authors: Stanislav I Svetlov; Victor Prima; Daniel R Kirk; Hector Gutierrez; Kenneth C Curley; Ronald L Hayes; Kevin K W Wang Journal: J Trauma Date: 2010-10
Authors: Jeremiah G Allen; Eric S Weiss; Mary Ann Wilson; George J Arnaoutakis; Mary E Blue; C Conover Talbot; Chunfa Jie; Mary S Lange; Juan C Troncoso; Michael V Johnston; William A Baumgartner Journal: Ann Thorac Surg Date: 2010-06 Impact factor: 4.330
Authors: Guy M McKhann; Maura A Grega; Louis M Borowicz; Michon Bechamps; Ola A Selnes; William A Baumgartner; Richard M Royall Journal: Arch Neurol Date: 2002-09
Authors: Marco Di Eusanio; Marc A A M Schepens; Wim J Morshuis; Roberto Di Bartolomeo; Angelo Pierangeli; Karl M Dossche Journal: J Thorac Cardiovasc Surg Date: 2002-12 Impact factor: 5.209
Authors: J M Redmond; A M Gillinov; K J Zehr; M E Blue; J C Troncoso; B A Reitz; D E Cameron; M V Johnston; W A Baumgartner Journal: J Thorac Cardiovasc Surg Date: 1994-03 Impact factor: 5.209
Authors: Marcos G Lopez; Christopher G Hughes; Anthony DeMatteo; Jason B O'Neal; J Brennan McNeil; Matthew S Shotwell; Jennifer Morse; Michael R Petracek; Ashish S Shah; Nancy J Brown; Frederic T Billings Journal: Anesthesiology Date: 2020-03 Impact factor: 7.892
Authors: Hari S Sharma; Dafin F Muresanu; Jose V Lafuente; Per-Ove Sjöquist; Ranjana Patnaik; Aruna Sharma Journal: Mol Neurobiol Date: 2015-07-01 Impact factor: 5.590
Authors: An N Massaro; Andreas Jeromin; Nadja Kadom; Gilbert Vezina; Ronald L Hayes; Kevin K W Wang; Jackson Streeter; Michael V Johnston Journal: Pediatr Crit Care Med Date: 2013-03 Impact factor: 3.624